Molecular and cellular prostate biology: Origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia

BJU International

Volumn 93, Issue SUPPL. 1, 2004, Pages 5-9

  Schalken, J A ^a,b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b Department of Urology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN EXPRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REVIEW;

EID: 1642388591     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410x.2003.04633.x     Document Type: Review

References (40)

1. Ku JH, Kim ME, Lee NK, Park YH, Ahn JO. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 2003; 61: 132-6
2. Lepor H, Owens RS, Rogenes V, Kuhn E. The detection of prostate cancer in males with prostatism. Prostate 1994; 25: 132-40
3. Meng FJ, Shan A, Jin L, Young CY. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev 2002; 11: 305-9
4. Partin AW, Carter HB, Chan DW et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-52
5. Lee C, Kozlowski JM, Grayhack JT. Aetiology of benign prostatic hyperplasia. Urol Clin N Am 1995; 22: 237-46
6. Winter JSD, Faiman C, Reyes F. Sexual endocrinology of fetal and perinatal life. In Austin CR, Edward RG eds, Mechanisms of Sex Differentiation in Animal and Man. New York: Academic Press, 1981: 205
7. Cunha GR. Epithelio-mesenchymal interactions in primordial gland structures which become responsive to androgenic stimulation. Anat Rec 1972; 172: 179-95
8. Xue Y, Sonke G, Schoots C et al. Proliferative activity and branching morphogenesis in the human prostate: a closer look at pre- and postnatal prostate growth. Prostate 2001; 49: 132-9
9. Cunha GR, Donjacour AM, Cooke PS et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-62
10. Krajewska M, Wang HG, Krajewski S, et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 1997; 57: 1605-13
11. Saez C, Gonzalez-Baena AC, Japon MA et al. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate 1999; 40: 83-8
12. Crescioli C, Villari D. Forti G et al. Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D(3) analogue. Mol Cell Endocrinol 2002; 198: 69-75
13. Niu Y, Xy Y, Zhang J, Bai J, Yang H, Ma T. Proliferation and differentiation of prostatic stromal cells. BJU Int 2001; 87: 386-93
14. Evans GS, Chandler JA. Cell proliferation studies in rat prostate I. The proliferate role of basal and secretory epithelial cells during normal growth. Prostate 1987; 10: 163-78
15. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999; 162: 293-306
16. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213-5
17. Wu CP, Gu FL. The prostate in eunuchs. EORTC Genitourinary Group Monograph 10. Urologic Oncology. Reconstructive Surgery, Organ Preservation and Restoration of Function. New York: Wiley-Liss, 1992: 249-55
18. Foster BA, Cunha GR. Efficacy of various natural and synthetic androgens to induce ductal branching morphogenesis in the developing anterior rat prostate. Endocrinology 1999; 140: 318-28
19. Avila DM, Fuqua SA, George FW, McPhaul MJ. Identification of genes expressed in the rat prostate that are modulated differently by castration and Finasteride treatment. J Endocrinol 1998; 159: 403-11
20. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990; 126: 1165-72
21. Coffey DS, Shimazaki J, Williams-Ashman HG. Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys 1968; 124: 184-98
22. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5: 545-57
23. Marks LS, Partin AW, Dorey FJ et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999; 53: 574-80
24. Staack A, Kassis AP, Olshen A et al. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 2003; 54: 212-9
25. Mahapokai W, Xue Y, van Garderen E, van Sluijs FJ, Mol JA, Schalken JA. Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. Prostate 2000; 44: 40-8
26. English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostote 1987; 11: 229-42
27. Xue Y, Smedts F, Verhofstad A, Debruyne F, de la Rosette J, Schalken J. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: new perspectives. Prostate (Suppl.) 1998; 8: 62-73
28. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate (Suppl.) 1989; 2: 33-50
29. Vailancourt L, Ttu B, Fradet Y et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 1996; 20: 86-93
30. Schroeder FH, Westerhof M, Bosch RJLH, Kurth KH. Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on six cases. Eur Urol 1986; 12: 318-21
31. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
32. Lee SO, Lou W, Hou M, Onate SA, Gao AC. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003; 22: 6037-44
33. Zhu YS, Cai LQ, You X, Cordero JJ, Huang Y, Imperato-McGinley J. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J Androl 2003; 24: 681-7
34. Xu J, Meyers DA, Sterling DA et al. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev 2002; 11: 664-9
35. Sica G, Zelano G, Settesoldi D, Iacopino F. Regulation of prostate-specific antigen gene expression by an LH-RH analogue in human prostatic cells. Anticancer Res 2003; 23: 1283-7
36. Brawer MK, Lin DW, Williford WO, Jones K, Lepor H. Effects of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate 1999; 39: 234-9
37. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G on behalf of the ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5 alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
38. Lilja H. Biology of prostate-specific antigen. Urology 2003; 62 (5 Suppl. 1): 27-33
39. Bostwick DG, Pacelli A, Lopez-Beltran A. Ultrastructure of prostatic intraepithelial neoplasia. Prostate 1997; 33: 32-7
40. Bostwick DG, Leske DA, Qian J, Sinha AA. Prostatic intraepithelial neoplasia and well differentiated adenocarcinoma maintain an intact basement membrane. Pathol Res Pract 1995; 191: 850-5